Multiple squamous cell carcinomas following introduction of nilotinib. (22nd August 2014) - Peters, P.
Summary Background Nilotinib is a second generation tyrosine kinase inhibitor, used in the treatment of chronic myelogenous leukaemia (CML). Methods We assessed a 72‐year‐old woman who was treated with nilotinib for CML. Results During the year following commencement of nilotinib, the patient developed eight squamous cell carcinomas (SCCs) on her legs. Conclusions Development of SCC is a previously unreported adverse reaction to nilotinib.